BRIEF-Viking Therapeutics Announces Initiation Of Phase 1 Study To Evaluate Novel Amylin Receptor Agonist Vk3019 In Healthy Adults

Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

VKTX

0.00

June 24 (Reuters) - Viking Therapeutics Inc VKTX.O:

  • VIKING THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 STUDY TO EVALUATE NOVEL AMYLIN RECEPTOR AGONIST VK3019 IN HEALTHY ADULTS

  • VIKING THERAPEUTICS - EXPECTS TO REPORT VK2735 DOSING STUDY RESULTS IN 3Q26

  • VIKING THERAPEUTICS - TO INITIATE PHASE 3 TRIAL OF ORAL VK2735 LATER THIS YEAR

Source text: ID:nPn1WpPSYa

Further company coverage: VKTX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.